latest news releases from the newsroom
Titanium Group Ltd.
Titanium Group Announces Contract With a Major Conglomerate in China
SAN JOSE, Calif., Feb. 14, 2007 (PRIME NEWSWIRE) -- Titanium Group, Ltd. (OTCBB:TTNUF), a leading biometric and security solutions provider, today announced a contract to provide its security solutions to Tsinlien Group and its subsidiary, Tianjin Development Holdings Limited (HKEX:0882), a conglomerate under the control of the Tianjin Municipal People's Government through its window company in Hong Kong, Tsinlien Group Company Limited. Tianjin Development Holdings Limited has approximately 3,800 employees with revenues exceeding US$286 million.
Infinity Pharmaceuticals, Inc.
Infinity and MedImmune Initiate Phase I/II Clinical Trial of IPI-504 for Patients With Non-Small Cell Lung Cancer
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Feb. 14, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced the initiation of a Phase I/II clinical trial of IPI-504, the companies' development-stage anti-cancer agent and heat shock protein 90 (Hsp90) inhibitor. In this study, which marks the second solid tumor indication in which IPI-504 is being tested, investigators will evaluate IPI-504 in patients with advanced non-small cell lung cancer (NSCLC). This open-label Phase I/II clinical trial of IPI-504 is being conducted at the Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI) in Boston, Mass.